Viatris Aims To Be At The Vanguard For Mammoth GLP-1 Opportunities
Recently Disclosed Tirzepatide Among Several Assets Viatris Plans To Take Forward
GLP-1s are all the rage in pharma, not least because of the commercial force of prescription brands like Wegovy. Viatris, which has molded into a more innovative-thinking company, has outlined its intentions to compete in the space.
